Bioequivalence of a biosimilar enoxaparin (Cloti‐Xa™) and its innovator (Clexane(®)): A single‐dose, randomized, double‐blind, two‐period, two‐treatment, two‐sequence, crossover, b...

por Saxena, Sumit, Chaudhary, Manu, Chaudhary, Saransh, Aggarwal, Anmol
Publicado 2022

Polymyxin B-Induced Kidney Injury Assessment of a Novel Formulation of Polymyxin B (VRP-034) in Rats

por Roy, Dilip, Kulkarni, Amol, Chaudhary, Manu, Chaudhary, Saransh, Payasi, Anurag, Aggarwal, Anmol
Publicado 2021

P07 Toxicokinetic profile of VRP-034

por Murkunde, Yogeshkumar Vishnupant, Chaudhary, Saransh, Vishwakarma, Kamlesh Kumar, Aggarwal, Anmol, Chilbule, Rahul
Publicado 2022

Ceftriaxone+Sulbactam+Disodium EDTA Versus Meropenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: PLEA, a Double-Blind, Randomized Non...

por Mir, Mohd Amin, Chaudhary, Saransh, Payasi, Anurag, Sood, Rajeev, Mavuduru, Ravimohan S, Shameem, Mohd
Publicado 2019

P06 Pharmacokinetics and renal accumulation of VRP-034

por Vishwakarma, Kamlesh Kumar, Chilbule, Rahul, Chaudhary, Manu, Sharma, Arun, Chaudhary, Saransh, Aggarwal, Anmol
Publicado 2022

P05 In vivo efficacy of VRP-034 in lung and thigh infection models

por Vishwakarma, Kamlesh Kumar, Payasi, Anurag, Kumar, Shailesh, Sharma, Arun, Chaudhary, Saransh, Aggarwal, Anmol
Publicado 2022

1373. Activity of Ceftriaxone–Sulbactam–EDTA Against Multi-Drug-resistant A. baumannii, P. aeruginosa and Enterobacteriaceae Isolates (WHO Critical Priority Pathogens) Collected fr...

por Girotra, Ruchi, Pyasi, Anurag, Chaudhary, Manu, Patil, N S, Mir, Mohd Amin, Chaudhary, Saransh, Mandale, Pankaj
Publicado 2018

1984. Ceftriaxone-Sulbactam-EDTA vs. Meropenem: Analysis of Failed Patients With Assessment of MIC Increases and Changes in Genotypic Profile in PLEA (a Phase 3, Randomized, Double...

por Mir, Mohd Amin, Chaudhary, Saransh, Chaudhary, Manu, Pyasi, Anurag, Patil, N S, Girotra, Ruchi, Narang, Salil, Fatima, Nazish
Publicado 2018

1974. Ceftriaxone-Sulbactam-EDTA vs. Meropenem in PLEA (a Phase 3, Randomized, Double-Blind Trial): Outcomes by Baseline MIC in Adults With Complicated Urinary Tract Infections or...

por Mandale, Pankaj, Mir, Mohd Amin, Chaudhary, Saransh, Chaudhary, Manu, Sood, Rajeev, Patil, N S, Narang, Salil, Pyasi, Anurag, Shameem, Mohammad
Publicado 2018

1959. Ceftriaxone-Sulbactam-EDTA (CSE) vs. Meropenem (MR) in PLEA (a Phase 3, Randomized, Double-Blind Trial): Outcomes in Patients Infected With Ceftriaxone Non-Susceptible, Exten...

por Mir, Mohd Amin, Chaudhary, Saransh, Mammen, Kim Jacob, Sood, Rajeev, Dogra, P N, Chadha, Sudhir, Mavuduru, Ravimohan, Sinha, Rahul Janak, Chaudhary, Manu, Shiekh, Gazalla
Publicado 2018